Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
纳武利尤单抗联合瑞拉利单抗和纳武利尤单抗联合伊匹木单抗治疗晚期肾细胞癌患者:来自开放标签、随机、II期FRACTION-RCC试验的结果
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.104073
Choueiri, T K; Kuzel, T M; Tykodi, S S; Verzoni, E; Kluger, H; Nair, S; Perets, R; George, S; Gurney, H; Pachynski, R K; Folefac, E; Castonguay, V; Lee, C-H; Vaishampayan, U; Miller, W H Jr; Bhagavatheeswaran, P; Wang, Y; Gupta, S; DeSilva, H; Lee, C-W; Escudier, B; Motzer, R J